MLYS - Mineralys Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$43.20
DETAILS
HIGH:
$56.00
LOW:
$30.00
MEDIAN:
$48.00
CONSENSUS:
$43.20
UPSIDE:
84.85%
About Mineralys Therapeutics, Inc. (https://mineralystx.com)
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Jon Congleton | President, Chief Executive Officer & Director | 1963 | $1,109,101 USD |
| James J. Ferguson FACC | Chief Medical Officer | 1954 | $881,798 USD |
| Adam Scott Levy | Chief Financial Officer & Secretary | 1978 | $880,190 USD |
| Brian Taylor Slingsby | Founder & Executive Director | 1977 | $78,000 USD |
| Danielle Mahoney | Senior Vice President of Quality Assurance | – | – |
| Eric J. Warren | Chief Commercial Officer | 1972 | – |
| Jeffrey A. Munsie | Chief Legal Officer | 1977 | – |
| Jessica Ibbitson | Executive Vice President of Operations | – | – |
| Jose Breton | Senior Vice President of Finance & Controller | 1989 | – |
| Michael Tortorici | Senior Vice President of Translational Medicine | – | – |
| Robert McKean | Senior Vice President of CMC | – | – |